Summary We measured serum concentrations of hapatocyte growth factor (HGF) in patients with gastric cancer and compared these with the histological findings and conventional tumour markers, including CEA, CA19-9 and CA125, for evaluation of the significance of serum HGF levels as a tumour marker. The HGF levels were measured by an enzyme-linked immunosorbent assay (ELISA) system. The average levels of serum HGF in 89 healthy control subjects, 104 patients with primary gastric cancer and 15 patients with recurrent gastric cancer were 0.31 ± 0.11 ng ml-1, 0.42 ± 0.50 ng ml-1 and 0.92 ± 0.39 ng mi-1 respectively. The average level in patients with recurrent disease was significantly higher than in healthy control subjects and in primary cancer patients (P< 0.001 and P< 0.003 respectively). Of 104 patients with primary gastric cancer, 35 (33.7%) showed an aberrant increase in the circulating level of HGF. The increased HGF levels were significantly associated with the degrees of histological tumour invasion and venous invasion. Of 15 patients with recurrent gastric cancer, 14 (93.3%) showed an aberrant increase. No correlation was found between serum HGF levels and CEA levels, CA19-9 levels and CA125 levels. However, the rate of the aberrant increase in HGF levels was significantly higher than that of any other tumour markers, including CEA, CAl 9-9 and CAl 25, in primary gastric cancer patients. In conclusion, the circulating levels of HGF were elevated in approximately one-third of patients with primary gastric cancer, particularly in those with high grades of histological tumour invasion and venous invasion, and frequently in patients with distant metastases, suggesting that HGF might play important roles in the tumour progression of gastric cancer. Furthermore, serum HGF levels may be of value as a tumour marker in patients with gastric cancer.
Hepatocyte growth factor (HGF) was first identified as a molecule that stimulates hepatocyte proliferation (Nakamura et al, 1984) . Later, it was known to be a multifunctional molecule for various types of cells, including endothelial cells and tumour cells. Particularly important biological activities of HGF in tumour cells are the ability to increase cell motility (Tajima et al, 1992) and to modulate angiogenesis (Rosen et al, 1990; Grant et al, 1993) as these are strongly associated with tumour invasion and the development of distant metastases. In recent clinical investigations, it was documented that HGF is a potent and independent predictor of recurrence and survival in primary breast cancer patients (Yamashita et al, 1994) . In addition, we have shown that serum HGF levels are frequently elevated in patients with recurrent breast cancer, in particular those with liver metastases (Taniguchi et al, 1995) . These findings indicate that elevation of circulating HGF is involved in the systemic progression of breast cancer.
In the gastrointestinal tract, HGF modulates intestinal epithelial cell proliferation and migration (Dignass et al, 1994) . It has been shown that c-Met, an HGF receptor, is frequently overexpressed in human gastric cancer cells and cancer tissues (Di Renzo et al, 1991) . Kuniyasu et al (1993) have demonstrated that 23% of primary gastric tumours show amplification of the c-met gene. Thus, we measured serum concentrations of HGF in patients with gastric cancer and compared them with the histological findings and conventional tumour markers, including CEA, CA19-9 and CA125, for evaluation of the significance of serum HGF levels as a tumour marker.
PATIENTS AND METHODS Patients and healthy control subjects
One hundred and four patients with primary gastric cancer and 15 with recurrent disease, treated at the Tokyo Metropolitan Komagome Hospital from 1991 to 1994, were enrolled in this study. The average age of the patients with primary gastric cancer was 64.0 years (range 31-88 years), including 74 men and 30 women. Patients with primary gastric cancer consisted of 28 stage I patients, 17 stage 11, 25 stage III and 34 stage IV, according to the General Rules for the Gastric Cancer Society, 12th edition, (which is based on the UICC criteria) by the Japanese Research Society for Gastric Cancer. The 15 patients with recurrent gastric cancer included six with liver metastases and nine without liver metastases, of whom eight had peritoneal recurrence and one had distant lymph node metastases. Liver and distant lymph node metastases were diagnosed by computerized tomographic (CT) scan. Patients with liver dysfunction due to hepatitis B and C virus infection and fatty degradation were excluded from this study. Eighty-nine healthy volunteers without any liver dysfunction, including 47 men and 42 women, were also enrolled in this study. Their average age was 49.7 years (range 40-59 years).
Samples
Venous blood samples were drawn into a tube and centrifuged at 3000 r.p.m. for 10 min, and the samples were stored at -20°C until Preparation of monoclonal antibody to human HGF Monoclonal antibody (MAb) against human hepatocyte growth factor (hHGF) was prepared according to the conventional procedure of Fuller et al (1987) . BALB/c mice were immunized subcutaneously with 30 jg hHGF in Freund's incomplete adjuvant. Mice were booster injected once with 10 jg hHGF in Freund's incomplete adjuvant. The mice were killed 3 days after the last immunization, and spleen cells were fused with NS-1 mouse myeloma cells using polyethylene glycol. To prepare MAb, established hybridoma cells were injected intraperitoneally into BALB/c and the MAbs were purified on a protein A-Sepharose column.
Enzyme-linked immunoassay
The level of HGF in sera was determined using an HGF-ELISA kit (Institute of Immunology, Tokyo, Japan). A specific sandwich method with a mouse monoclonal antibody to recombinant human hepatocyte growth factor (anti-HGF-a chain antibody) and mouse monoclonal antibodies labelled by peroxidase was used in this ELISA system. Twofold diluted sera were used for the measurement of HGF (Yamada et al, 1995) . The standard curve of HGF showed absorbance linearity from 0.10 to 6.4 ng m1' (Figure 1 ). The limit of detection in this kit is 0.10 ng ml-'.
Measurement of CEA, CA19-9 and CA125 in sera
The levels of CEA, CA 19-9 and CA125 in the same serum sample were examined using the ELISA system. The cut-off levels for CEA, CA19-9 and CA125 were 6.2 ng mP, 58.0 U ml-l and 35.0 U ml' respectively.
Histological diagnosis
Thin sections of about 5 jim thickness were cut from surgical large sections with a microtome. These were mounted on large glass slides and stained with haematoxylin-eosin and elastica van (Ming, 1977) . All tissue specimens were examined by pathologists.
Statistical analysis
The Student's t-test was used for analyses of unpaired samples, and the paired t-test was used when samples were paired. The chisquared test was also used to test the significance between two groups. Correlation was assessed using Spearman's correlation coefficiency by rank. Table 3 ). In contrast, there was no significant correlation between serum HGF levels and the degrees of paragastric lymph node metastases and that of intratumoral lymphatic invasion. There was also no significant difference between serum HGF levels of differentiated type and those of undifferentiated type (Table 3) . In comparison with conventional tumour markers for gastric cancer, serum HGF levels were elevated in 69 (33.7%) of 104 patients with primary gastric cancer. Serum CEA levels, serum CAl9-9 levels and serum CA125 levels were elevated in 21 (20.2%), 14 (13.5%) and 15 (14.4%) cases respectively. There were statistically significant differences between HGF levels and CAl9-9 levels in stage II (P < 0.04) and in stage III (P < 0.04) patients. Also, there were significant differences between HGF levels and CA125 levels in stage II (P < 0.04) and in stage III patients (Table 4) . No significant correlation was seen between serum HGF levels and serum CEA levels, CA19-9 levels and CA125 levels (data not shown). Of 15 patients with recurrent gastric cancer, 14 (93.3%) exhibited HGF levels > 0.4 ng ml,-1 in the serum. The mean value of serum HGF levels in patients with recurrent gastric cancer was 0.92 ± 0.39 ng ml-' and a significant difference was found when compared with HGF levels in healthy controls and in patients with primary gastric cancer (P < 0.0001 and P < 0.003 respectively) (Figure 1 ). Patients with primary gastric cancer had higher levels There was no significant correlation between serum HGF levels and conventional tumour markers (data not shown). *P, HGF vs CEA; **P, HGF vs CAl 9-9; ***P, HGF vs CA125. NS, not significant. Figure 2 The circulating level of HGF in healthy control subjects (n = 89), in patients with primary gastric cancer (n = 104) and in patients with recurrent disease (n = 15). *P = 0.054, **P > 0.001, *** P > 0.003 of serum HGF than healthy control subjects but there was no significant difference between the two groups (P = 0.054). No significant difference was found between recurrent patients with liver metastases (n = 6) and those without liver metastases (n = 9).
DISCUSSION
In this study, we found an aberrant increase in serum HGF levels in patients with gastric cancer. Male patients had apparently higher circulating levels of HGF than female patients because of the different proportions in clinical stage between male patients and female patients (data not shown). In patients with primary gastric cancer, there was a significant correlation between the elevation of serum HGF levels and the high degree of histological tumour invasion and venous invasion, whereas we could find no significant correlation between HGF levels and degrees of histological nodal metastases (n) and lymphatic invasion (ly). Furthermore, the average circulating level of HGF in patients with recurrent gastric cancer was significantly higher than that in healthy controls (P < 0.001) and in patients with primary disease (P < 0.003). The average level in patients with primary gastric cancer was apparently higher than that in healthy control subjects (P = 0.054). We have not studied whether the circulating level of HGF in patients with primary gastric cancer would decrease after gastrectomy. The circulating level of patients with breast cancer was significantly decreased after mastectomy (Taniguchi et al, 1995) and pleural effusion samples, which were obtained from patients with lung cancer and various types of malignant disease, contained high levels of HGF (Eagles et al, 1996) . These observations strongly suggest that increased circulating levels of HGF are related to progression of various types of malignant tumour, including gastric cancer. In fact, it was documented that 55% of gastric carcinoma cell lines and 23% of advanced gastric carcinomas show c-met gene amplification; the c-met gene was expressed in all of the tissue samples not only from gastric carcinoma tissue but also from normal stomach mucosa (Kuniyasu et al, 1993) . Immunohistochemically, HGF was also identified from fibroblasts on the gastric wall. Furthermore, a recent study noted that Helicobactor pylori, which induces hyperproliferation of the gastric mucosa, stimulates the expression of HGF in human gastric mucosa (Kondo et al, 1995) . Thus, there are many experimental and clinical data that indicate that HGF might play an important role in tumour development and growth of human gastric cancer. HGF is secreted as a single-chain biologically inactive precursor (pro-HGF), mostly found in a matrix-associated form (Naka et al, 1992; Naldini et al, 1992) . In vitro, this pro-HGF is converted to the active mature HGF heterodimer by pure urokinases (Naldini et al, 1995) which are the most commonly expressed proteases in solid tumours, including stomach cancer. In addition, the prognostic value of urokinases has been noted in various types of tumours (Foekens et al 1995; Hildenbrand et al, 1995) . Several cytokines and growth factors, including interleukin 1 a and 1 and tumour necrosis factor-a from stromal cells can modulate the production and secretion of hHGF (Tamura et al, 1993) . On the other hand, transforming growth factor -, is known to be primarily responsible for mediating the down-regulation of HGF production in fibroblasts (Seslar et al, 1995) . Such interactions between epithelial cells and mesenchymal cells are thought to be crucial for the regulation of HGF activities in cancer invasion and metastasis. Recently, we found a marked induction of serum HGF by heparin (Taniguchi et al, 1994) . Therefore, heparin activities, which are also noted to regulate stromal cells through the activation of proteases, seem to be important for the regulation of HGF in serum. For breast cancer patients, we have also found an increase in the circulating level of HGF. Also in breast cancer, the aberrant increase in HGF was significantly associated with the number of axial lymph node metastases and the venous invasion grade (Taniguchi et al, 1995) , suggesting that the induction of HGF in sera associated with tumour progression may be a general event in various types of human tumours. Although we have not examined intratumoral HGF concentrations in gastric cancer tissues, some mediators, such as injurin, may be involved in the elevation of HGF in the serum.
There was no significant correlation between HGF and other conventional tumour markers in 104 patients with primary gastric cancer. The positive rate of HGF elevation was higher than that of any other tumour marker, including CEA, CA19-9 and CA 125, in every clinical stage. Particularly in patients with stage II or stage III gastric cancer, there was a significant difference between HGF CAl9-9 and CA125. Recently, various tumour markers for gastric cancer were reported from many clinical institutes, including CA72-4, TPA and CA50 (Guadagni et al, 1992; Wobbes et al, 1992) . However, after a review of the literature, the measurement of serum HGF levels seems to be the most sensitive method for monitoring tumour progression in gastric cancer. Furthermore, the elevation of HGF seems to affect the biological activities of tumour cells in the same way as an endocrine growth factor. We consider that serum HGF level may be a promising tumour marker in patients with gastric cancer.
In conclusion, the aberrant increase in serum HGF levels seems to be associated with tumour progression in gastric cancer, suggesting that the suppression of HGF activities may be of value as a treatment for patients with gastric cancer. ABBREVIATIONS HGF, hepatocyte growth factor; CEA, carcinoembryonic antigen
